Niraparib: A Review in Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Targeted Oncology"
DOI: 10.1007/s11523-018-0582-1
Abstract: Niraparib (Zejula®), a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for the maintenance treatment of recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based… read more here.
Keywords: peritoneal cancer; tube primary; fallopian tube; ovarian fallopian ... See more keywords